drugset / Trial / NCT05379647
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in combination with Rituximab in relapsed/refractory B-cell Lymphoma. This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-019a in patients with relapsed/refractory B-cell lymphoma or B-ALL. Up to 22-36 patients will be enrolled.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2024-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QN-019a | Cell therapy | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |